B-cell acute lymphoblastic leukemia (ALL) can recur when leukemic cells become resistant to chimeric antigen receptor (CAR) T-cell therapy, according to a report from the University of Pennsylvania’s Abramson Cancer Center, in Philadelphia.
A leukemic cell inadvertently engineered with leukemia-targeting CAR lentivirus and infused into a patient can reproduce and cause a deadly recurrence of B-cell ALL, according to a team of researchers from the center (Nat Med 2018;24[10]:1499-1503).
